Vertex Pharmaceuticals has announced a broad reimbursement agreement with NHS England for its cystic fibrosis (CF) treatment ALYFTREK (deutivacaftor/tezacaftor/vanzacaftor), following a positive final draft recommendation from the National Institute for Health and Care Excellence (NICE).
ALYFTREK is a triple combination therapy approved for patients aged six and older who carry at least one F508del or other responsive mutation in the CFTR gene, the genetic root of cystic fibrosis.
“We’re proud that ALYFTREK, our fifth CF medicine, is now available as an option for all eligible CF patients in England,” said Ludovic Fenaux, Senior Vice President at Vertex International. He highlighted the drug’s potential to deliver improved outcomes compared to the existing treatment KAFTRIO (ivacaftor/tezacaftor/elexacaftor).
With recent European regulatory approval, patients in Ireland, Denmark, and Germany will be among the first in the EU to access the therapy. Vertex is actively engaging with reimbursement authorities across the European Union to expand availability to all eligible patients as swiftly as possible.
This agreement marks a significant step in Vertex’s ongoing mission to advance treatments for people living with cystic fibrosis worldwide.